http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2461386-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c2e449ea8d5757954aabd9b51a86c3a8 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 |
| filingDate | 2011-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbc23cfcae4a40cbd8e7225e8f36639a |
| publicationDate | 2012-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2461386-C1 |
| titleOfInvention | Use of uglanex as lipid, carbohydrate and protein normalising drug |
| abstract | FIELD: medicine. n SUBSTANCE: invention refers to medicine, namely therapy and endocrinology, and may be applicable as a lipid, carbohydrate and protein normalising drug in treating type II diabetes mellitus, atherosclerosis and metabolic syndrome. That is ensured by adding the integrating therapy with the drug Uglanex. n EFFECT: invention provides effective treatment of said pathological conditions ensured by reducing a cholesterol level, an atherogenicity index, blood sugar, insulin resistance and albuminuria. n 3 tbl |
| priorityDate | 2011-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 164.